GRASTEK

Timothy Grass Pollen Allergen Extract

ATC

Added

9 months ago on 22 May 2017

Drug information on epgonline.org reflects the approved license for the product. We do not hold any information on availability, reimbursement or local recommendations. We do not sell or supply any drug products; please contact your local pharmacy/formulary.

Indication(s)

GRASTEK is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens. GRASTEK is approved for use in persons 5 through 65 years of age. (1)

Related Content

The TENOR (The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens) study is an ongoing three-year multi-center observational cohort study of 4756 severe or difficult-to-treat patients with asthma aged 6 or older.

While increased asthma morbidity and mortality have been observed across all ethnicities, results from several studies have found that asthma morbidity has increased disproportionately in low-income African American children.

The objective of this randomized, double blind, sham-controlled study is to demonstrate the safety and effectiveness of the Alair System in a population of subjects with severe asthma who are still symptomatic.

Chronic respiratory diseases are a significant cause of morbidity and mortality worldwide. We sought to evaluate the impact of asthma, chronic bronchitis and allergic rhinitis on all-cause hospitalizations...

The American Academy of Otolaryngic Allergy (AAOA) convened an expert, multidisciplinary Working Group on Allergic Rhinitis to discuss patients' self-treatment behaviors and how health care providers approach and treat the condition.

Few studies have directly compared the efficacy of intranasal corticosteroids with that of leukotriene receptor antagonists for the treatment of daytime and nighttime symptoms of seasonal allergic rhinitis (SAR).

The present guideline (S2k) on allergen-specific immunotherapy (AIT) was established by the German, Austrian and Swiss professional associations for allergy in consensus with the scientific specialist societies and professional associations...

Allergic rhinitis (AR) affects more than 20% of the population in the United Kingdom and western Europe and represents a major cause of morbidity that includes interference with usual daily activities and impairment of sleep quality.

Advisory information

• Severe, unstable or uncontrolled asthma. (4)
• History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy. (4)
• A history of eosinophilic esophagitis. (4)
• Hypersensitivity to any of the inactive ingredients contained in this product. (4)

WARNING: SEVERE ALLERGIC REACTIONSSee full prescribing information for complete boxed warning.
• GRASTEK can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction. (5.1)
• Do not administer GRASTEK to patients with severe, unstable or uncontrolled asthma. (4)
• Observe patients in the office for at least 30 minutes following the initial dose. (5.1)
• Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use. (5.2)
• GRASTEK may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction. (5.2)
• GRASTEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers. (5.2)

• Inform patients of the signs and symptoms of serious allergic reactions and instruct them to seek immediate medical care and discontinue therapy should any of these occur. (5.1)
• In case of oral inflammation or wounds, stop treatment with GRASTEK to allow complete healing of the oral cavity. (5.7)

Usage information

For sublingual use only. (2)
• One tablet daily. (2.1)
• Initiate treatment at least 12 weeks before the expected onset of each grass pollen season and continue treatment throughout the season. For sustained effectiveness for one grass pollen season
after cessation of treatment, GRASTEK may be taken daily for three consecutive years. (2.2)
• Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute. (2.2)
• Administer the first dose of GRASTEK under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases. Observe patients in the office for at least 30 minutes following the initial dose. (2.2)